USARAPP▼
Rapport Therapeutics reports Q2 net loss of $56.6 million
Rapport Therapeutics reported a second-quarter net loss of $56.6 million, compared to $26.7 million in the prior year period. The company expects that its cash, cash equivalents, and short-term investments as of June 30, 2026 will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2029.